Evidence map›Paper›PMID 41152811›Full record

ArticleBMC urology2025

The utility of radiopharmaceutical uptake in the bladder neck and prostate on preoperative FDG PET/CT in determining urethral surgical margin positivity in patients undergoing radical cystoprostatectomy for bladder cancer.

Resat Aydın, Rifat Burak Ergül, Anıl Tantekin, Yasemin Sanlı, Selcuk Erdem, Mehmet Oner Sanlı, Faruk Ozcan

Abstract read
In one paragraph

Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Resat AydınDepartment of Urology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey. resatdoktor@hotmail.com.
Rifat Burak ErgülDepartment of Urology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey.
Anıl TantekinDepartment of Urology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey.
Yasemin SanlıDepartment of Nuclear Medicine, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey.
Selcuk ErdemDivision of Urologic Oncology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey.
Mehmet Oner SanlıDivision of Urologic Oncology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey.
Faruk OzcanDivision of Urologic Oncology, Istanbul University Istanbul Faculty of Medicine, Istanbul, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBladder cancer is the most common malignancy of the urinary system. It is a heterogeneous type of cancer with a high potential for metastasis, approximately 25% of which occurs as muscle invasive. As with other malignancies, accurate and precise staging of bladder cancer is one of the mainstays for choosing the most appropriate treatment for the patient. Detection of metastasis is extremely important in choosing the treatment strategy. FDG PET/CT is widely used in the clinical management of various malignancies and is increasingly used in the primary staging of muscle-invasive bladder cancer and detection of recurrence after radical cystectomy. We aimed to determine the role of radiopharmaceutical uptake in the bladder neck and prostate region in preoperative FDG PET/CT in patients with muscle-invasive bladder tumors in determining the positivity of prostatic urethra surgical margins in the final pathology after cystectomy and its effect in determining the type of diversion to be chosen.

methodsThe data of male patients who underwent FDG PET/CT before radical cystectomy due to MIBC between January 2009 and January 2023 in the Department of Urology at Istanbul Faculty of Medicine were retrospectively analyzed. The correlations between the presence of radiopharmaceutical uptake in the bladder neck or prostate in FDG PET CT and the positivity of the prostatic urethra surgical margin in the postoperative final pathology of these patients and the invasion of urothelial carcinoma in the prostate were analyzed.

resultsProstatic urethra surgical margin positivity was detected in 8 of 50 male patients who had FDG PET CT in the preoperative period. Prostatic urethra surgical margin positivity was detected in 5 of 19 patients with bladder neck and prostate region involvement on FDG (p = 0.2554). Prostate involvement was seen on FDG in 6 of 9 patients with urothelial carcinoma invasion into the prostate (p = 0.1492). Prostate adenocarcinoma was observed in the final pathology of 12 patients, and 8 of these patients had FDG uptake (p = 0.106). While no statistically significant relationship was found between the presence of bladder neck and prostate region involvement on FDG and prostatic urethra surgical margin, urothelial carcinoma invasion into the prostate and prostate adenocarcinoma, a statistically significant relationship was observed between the presence of malignancy in the prostate (urothelial carcinoma and/or adenocarcinoma) (p = 0.0189).

conclusionsWhile no statistically significant relationship was found between radiopharmaceutical uptake in the bladder neck and prostate region on preoperative FDG PET CT in CIBC and prostatic urethra surgical margin positivity, urothelial carcinoma invasion into the prostate and the presence of prostate adenocarcinoma; It was found valuable in detecting the presence of malignancy in the prostate (adenocarcinoma/urothelial carcinoma).

Indexed as

CystectomyFluorodeoxyglucose F18Margins of ExcisionPositron Emission Tomography Computed TomographyProstateProstatectomyRadiopharmaceuticalsUrethraUrinary BladderUrinary Bladder NeoplasmsAgedHumansMaleMiddle AgedPreoperative CareRetrospective StudiesFluorodeoxyglucose F18RadiopharmaceuticalsBladder neck and prostate uptakeFDG PET/CTMuscle-invasive bladder cancer (MIBC)Prostatic urethral surgical marginRadical cystoprostatectomyUrothelial carcinoma invasion

Identifiers

PMID41152811
PMCPMC12570415

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.